cells

Colorectal Clinical Trials

Colorectal Cancer (ARC-9)

Overview

A randomized Phase 1b/2, open-label, multi-center platform study to evaluate the efficacy of etrumadenant (AB928)-based combinations in patients with metastatic colorectal cancer.

Key Eligibility Criteria

  • Histologically confirmed metastatic colorectal adenocarcinoma
  • Inclusion Criteria for Cohort A:
    • Disease progression following not more than one prior line of treatment for mCRC that consisted of oxaliplatin or irinotecan containing chemotherapy in combination with a biologic agent
  • Inclusion Criteria for Cohort B:
    • Disease progression during or following not more than two separate lines of treatment for mCRC that consisted of oxaliplatin, and irinotecan containing chemotherapy in combination with a biologic agent
  • Inclusion Criteria for Cohort C:
    • Disease progression during or following more than three separate lines of treatment for mCRC

ARC-9 Clinical Trial Locations

clinicaltrials.gov

arrow